Loading...
Gadolinium-based contrast agents for magnetic resonance imaging — which earned a boxed warning in 2007 against their use in patients with severe renal insufficiency — now must carry additional information on the risks involved. (The 2007 warning specified that the agents could cause nephrogenic systemic fibrosis in such patients).
The FDA says that three agents are of greatest concern: Magnevist, Omniscan, and Optimark. Patients with acute kidney injury or chronic severe kidney disease (with glomerular filtration rates under 30 mL/min) seem most at risk.
Among the recommendations are the need to screen patients for acute kidney injury or chronic kidney disease, and to not repeat administration of any gadolinium-based contrast agent during a single imaging session.
Comment
LINK(S):
FDA announcement (Free)
Physician's First Watch coverage of 2007 label change (Free)